Toggle

CAR T cells (CD70) to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), lymphoma,  myelodysplastic syndrome (MDS) or mixed phenotype acute leukemia (MPAL) that has come back (relapsed) or not gotten better with treatment (refractory) in children, teens and young adults

Print

21 and younger

Phase 1

1 Location

NCT06326463

Clinical Trial Goal


To find out:
  • The highest dose of CAR T cells that's safe to give
  • If CAR T cells are safe and work well to treat ALL, AML, lymphoma or MDS that has relapsed or is refractory in children, teens and young adults

You may be able to join this trial if you:


Your child:
  • Is 0 - 21 years old 
  • Has one of the following that has relapsed or is refractory:
    • ALL
    • AML
    • Lymphoma
    • MDS
    • MPAL
  • Has cancer cells with mutation/marker CD70 (CD70+). Your child's doctor can tell you this
  • Does not have acute promyelocytic leukemia
  • Does not have graft-versus-host-disease (GVHD)
  • You agree to have other standard tests done to see if your child can be in the clinical trial

Trial Details


CAR stands for chimeric antigen receptors and T stands for T cells, a type of immune cell. This treatment helps your own immune system find and destroy cancer cells.
Cyclophosphamide and fludarabine are chemotherapy (chemo) drugs that block the growth of cancer cells. 
Mesna is a drug that protects the bladder from the side effects of certain chemo medications. 

To make CAR T cells, T cells are collected from your child by apheresis. Apheresis is a process to collect cells from the bloodstream using a needle similar to when you donate blood. The T cells are genetically modified to grow special proteins called CARs. CARs help T cells find the cancer cells. The CAR T cells are grown in a lab until there are millions of them. Then, they’re given back to your child to find and destroy the cancer cells.
 
Before the CAR T-cell infusion, your child will get chemotherapy (chemo) with 2 of standard drugs:
  • Cyclophosphamide – Given as intravenous (IV) infusions 2 times
  • Fludarabine –  Given as IV infusions 3 times

Then, the CAR T cells are given to your child through an IV infusion. The dose of cells your child will get depends on when they start the trial and how safe it has been.

Your child will have biopsies and/or scans to see how well the treatment is working.

The Food and Drug Administration (FDA) has not yet approved this type of CAR T-cell therapy. 

Watch a video about CAR T-Cell Therapy

Contacts


Swati Naik, MBBS, 866-278-5833, referralinfo@stjude.org

Locations


St. Jude Children's Research HospitalRECRUITING

Memphis, Tennessee
Swati Naik, MD, 866-278-5833, referralinfo@stjude.org

ClinicalTrials.gov record


NCT06326463. First posted on 3/22/24

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator

1-888-814-8610
contact@ctsearchsupport.org